A continent that relies on foreign drugs is now setting up the drug factories. The government under the 24-Hour Economy programme is planning to develop a pharmaceutical industrial park occupying an estimated 2,000 acres in the Shai-Osudoku District of Ghana. It will feature an integrated environment for the manufacturing of drugs, medical devices, herbal medicine, research and development, and allied health products.
According to Citi Newsroom, pre-feasibility studies are now complete, an anchor investor is already secured and a long list of tenants from India, China, and the United States are in active discussions. Today, about 70 per cent of Ghana’s pharmaceuticals are imported, which is a structural weakness the park is aimed at correcting.
The news is not a red flag or a rumour for the entrepreneurs, MSME manufacturers, exporters and investors who keep a close eye on the African pharma market. It’s like a starting gun. The ecosystem is in the design phase. A single building hasn’t been built yet, but supply chains, tenant roles and technology partnerships are being formed. The firms involved will shape the future of West African drug production over the next 20 years.
What Recent Reporting Means: Three Business Signals Founders Should Not Miss
The news about the park was announced by the Head of Project Development of the 24-Hour Economy Secretariat, Kafui Linda Abbah-Foli, at the 2026 China-West Africa Medical and Health Industry Expo in Accra. In her remarks, she included very specific commercial signals that business planners should take actions on.
First: Infrastructure is being made available at the park level. Roads, electrical, water and wastewater treatment systems will be managed centrally. This one cost and operational hurdle alone is so great that it will keep pharmaceutical manufacturers out of the African markets. A tenant manufacturer comes into a plug and produces scenario.
Secondly the government is targeting the entire value chain. As Citi Newsroom reported, Abbah-Foli stated the goal is to build a park that caters for the whole value chain — from active pharmaceutical ingredients and excipients through to finished dosage forms, medical devices, and health technologies. This does not restrict the opportunity to a single product type. The full vertical, starting from raw material processing to finished medicine packaging is up for investment.
Thirdly, community equity is a different model of land acquisition from the ones that have proven unsuccessful in other parts of West Africa. The project will be a shared enterprise, with traditional authorities and land owners becoming shareholders of the project with the benefit of dividends and rental income. This design avoids the land dispute Issues that have hampered similar projects in Nigeria, Cameroon and Senegal.
To entrepreneurs, MSMEs, manufacturers, investors and exporters, the implications are three-fold; three things that will be available from the moment the operations begin; first-mover positioning, implicit guarantee of ‘buy-in’ to the government to buy in the products of import substitution and a regional export market of 430 million people for any facility in Ghana.
Why Ghana’s Pharmaceutical Manufacturing Sector Is a Structural Growth Story
COVID-19 has shown the continent’s vulnerability to drug imports. The Coronavirus Disease (COVID-19) has made it clear that Africa is at risk because of the dependence they have on drugs from abroad. Publicly, governments across the continent agreed to develop local production capacity. Today, Ghana is turning that promise into investments in infrastructure. However, the need fundamentals are structural and self-reinforcing, beyond political will.
The burden of diseases in Ghana is changing. Non-communicable diseases (NCDs) such as diabetes, hypertension, stroke and cardiovascular diseases are escalating rapidly among urban populations. The medications must be taken regularly over a long period of time for these conditions. This means predictable, recurrent demand for medicines which Ghana imports virtually from India and China. If just a small portion of these needs can be satisfied at home, it is a potential multi-hundred-million-dollar market opportunity.
The NHIS is a structured and funded buyer of essential medicines. Government procurement policy clearly prioritizes products manufactured locally when there are competitive quality and price. A manufacturer within the park will be present, with virtually guaranteed public sector off-take as soon as it gets to market.
At the continental level, the Africa Medicines Agency (AMA) develops a streamlined approval process to enable a product approved in Ghana to be sold in other countries in the continent with less duplication. A facility in the Shai-Osudoku Park will support Ghana’s membership of ECOWAS and the African Continental Free Trade Area (AfCFTA), meaning that it will facilitate the integration of the 54 countries of Africa within a single regulatory and trade framework.
Government Policies and Incentives: What Manufacturers Need to Know
Ghana has put in place an integrated system of institutions and incentives tailored to reduce the cost and complexity of investment in the manufacture of pharmaceuticals. For any entrepreneur or manufacturer who’s thinking about getting into a new market, knowing what each body does — and where — is vital.
The Ghana Investment Promotion Centre (GIPC) is the main agency providing services to all foreign and local investors. GIPC is responsible for investment registration, access to sector-oriented incentives and sector facilitation in government ministries. GIPC grants pharmaceutical investors duty exemptions on imported plant, machinery, and critical raw materials, helping them substantially reduce upfront capital expenditure.
The pharmaceutical park will be gazetted as a Free Zone and manufacturers will be eligible for benefits offered by the Ghana Free Zones Authority (GFZA) such as a 10-year corporate income tax holiday and 100% exemption from customs duties on capital equipment and production inputs. Effective first decade tax burden can be effectively reduced to almost zero for a manufacturer through this incentive framework.
The Ghana Export Promotion Authority (GEPA) offers market development assistance, export facilitation and international buyer networks that are of great benefit to manufacturers with export aspirations, especially those targeting markets in the ECOWAS and institutional buyers like UNICEF Supply Division and Global Fund.
The Food and Drugs Authority (FDA) Ghana is responsible for regulatory licensing for pharmaceutical manufacturing. The FDA grants Manufacturing Authorisations and carries out WHO Good Manufacturing Practice (GMP) inspections. Close cooperation with the FDA should be established from the outset of the process, because the GMP facility design needs to be built into the process from the start.
Related Article: India’s Pharma Boom: 5 Startup Opportunities You Can’t Ignore
Industrial Park policy and inter-ministerial coordination flow through the Ministry of Trade and Industry (MoTI), which works in close coordination with the 24-Hour Economy Secretariat on park development, zoning, and anchor investor contracting. The National Development Planning Commission (NDPC) provides the long-term industrialisation policy framework within which the pharma park sits as a flagship project.
Tax administration, including holiday applications and capital investment allowances, is handled by the Ghana Revenue Authority (GRA). Quality standards and manufacturing certifications aligned with WHO GMP are set and enforced by the Ghana Standards Authority (GSA). Both bodies should be engaged during the pre-construction design phase.
The direct project implementing authority — and first point of contact for all tenant and investor enquiries — is the 24-Hour Economy Secretariat. Project development activities for the park should finish by the end of 2026, making the current period the optimal window for prospective tenants to register their interest and influence the master planning process.
Six Manufacturing Business Opportunities Emerging Directly from the Park
1. Generic Essential Medicines Manufacturing
Ghana has 70 per cent of its pharmaceutical needs imported and, therefore, there is a guaranteed market for the production of essential medicines. There are opportunities for the production of Paracetamol, Amoxicillin, Metformin, Antihypertensive tablets and Oral Rehydration salts (ORS) as well as Antimalarial tablets. The park’s infrastructure removes the capital hurdle, while WHO’s pre-qualification opens up institutional off-take avenues with organizations such as UNICEF, the Global Fund, and NHIS. This represents the biggest opportunity among the range of product intended in the park as stated by Abbah-Foli about the increasing NCD burden in Ghana.
2. Active Pharmaceutical Ingredient (API) Manufacturing
Ghana is now importing finished medicines, as well as the raw materials used to produce medicines (active pharmaceutical ingredients and excipients) by its own local producers. This double dependence creates both a vulnerability, and an opportunity. An API plant within the park will be able to serve the domestic formulators at prices that are below import parity and will export surplus production to other manufacturers in West Africa. Chemically intensive, waste-producing API synthesis is an option at the scale of the park because of the shared effluent treatment system.
Read the Complete Book Here: Handbook on Active Pharmaceutical Ingredients (API), Drugs & Pharmaceutical Products
3. Herbal Medicine and Standardised Botanical Extracts
The mandate of the park says expressly herbal medicine. Plants in Ghana, with established medicinal properties against skin diseases, diabetes, inflammation and malaria are part of the country’s botanical biodiversity. A manufacturing facility that can produce GMP certified botanical extracts, capsules, tinctures, and standardised herbal formulations is able to gain access to the traditional medicine market in Africa, as well as the rapidly expanding global market for nutraceuticals and natural health products, where buyers from Europe, North America, and Asia are actively seeking certified Africa-origin supply chains.
Explore This Book: Herbal Medicines Manufacturing Handbook
4. Medical Device and Diagnostic Equipment Assembly
There is a huge deficiency of diagnostic equipment in West Africa. Medical device production is directly mandated in the park’s mandate. Access to the park’s ecosystem is possible with low capital investment. Businesses can establish assembly plants for glucometers, blood pressure monitors, pulse oximeters, thermometers, and rapid diagnostic test (RDT) kits. These plants can use imported components. The medical device registration pathway through FDA Ghana is clearly defined and attainable. Local assembly can give Ghana a long-term competitive advantage over full imports. It can also improve access to diagnostics across the ECOWAS region.
Get Detailed Project Report (DPR): Medical Devices & Disposables Industry in India
5. Pharmaceutical Packaging Materials Manufacturing
All tablets, capsules, and liquid medicines made in the park must be packaged in HDPE bottles, blister packs, aluminium foil laminates, glass vials, printed cartons, and labels. Currently, Ghana imports most pharmaceutical-grade packaging materials. A packaging plant in or near the park can start with a built-in customer base. The other companies in the park can become its first customers. The regulatory barrier is also lower because the plant needs to meet pharma-grade packaging standards rather than drug GMP requirements. Proximity also creates a supply advantage through faster delivery, better responsiveness, and competitive local pricing.
6. Cold Chain Logistics and Pharmaceutical Warehousing
For specialty generics, biologics, vaccines and insulin, Ghana urgently needs validated cold-chain storage and distribution infrastructure. Currently, such infrastructure is in limited supply.
As the park’s production capacity increases, demand for GMP-compliant cold storage will grow significantly. There will also be a need for pharmaceutical-grade distribution vehicles and last-mile delivery services. These services will support hospitals, clinics and pharmacies across Ghana and the ECOWAS region.
A new cold-chain logistics company can be developed alongside the park. It would provide essential logistics support to all tenant manufacturers. It could also strengthen Ghana’s public health supply chain.
Import–Export Opportunity Analysis
Export Markets: ECOWAS and Beyond
By joining the ECOWAS, any manufacturer in the park can access 15 national markets across West Africa on day-one. The biggest local markets for generic medicines, diagnostics and health consumables are Nigeria (220 million people), Côte d’Ivoire, and Senegal, and Burkina Faso. The ECOWAS pharmaceutical harmonisation framework provides for less duplication of regulatory applications for products registered in Ghana. In addition to ECOWAS, the AfCFTA is opening the continental market, while Ghana’s EU-ACP agreements and access to AGOA offer routes for institutional procurement in Europe and North America.
Import Substitution: A Policy-Backed Opportunity
Ghana’s pharmaceutical market is structurally under-supplied because 70 per cent of the country depends on imports for its needs. The government’s procurement policies explicitly prefer locally produced goods for which there is evidence of quality and competitiveness. This is not an abstract market — each medicine produced locally replaces a similar amount of money spent on importing medicines. The government’s comprehensive 24-Hour Economy policy further embodies this focus by supporting industries through facilitation in industrial zones, regulation and proactive investment promotion.
International Demand and Technology Transfer
Commercial value comes from the confirmed presence of Indian, Chinese, and US companies in the park’s tenant pipeline. The Ghana market offers international manufacturers a strong entry point into West Africa. Local Ghanaian entrepreneurs can also pursue structured joint ventures, contract manufacturing, and technology transfer opportunities by contributing regulatory relationships, community connections, and local market knowledge—areas that foreign investors specifically need.
Indian MSME Success Stories in Comparable Markets
Indica Laboratories — Generic Medicines for Africa
In the early 2010s, Indica Laboratories, a medium-sized generic drug company from Vadodara, Gujarat, developed a niche export strategy for Africa. Today, Indica distributes its products across 14 African countries. The company focused on WHO pre-qualification for anti-malarial, anti-retroviral, and anti-TB product lines. It also built partnerships with regional distributors. This model shows that a well-funded MSME can build a substantial pharma export business in Africa within 10 years. However, it requires the right regulatory investments and a focused market strategy.
Vasudha Pharma Chem — API Manufacturing at Scale
Vasudda Pharma Chem is an API manufacturer based in Hyderabad. The company grew from an MSME into an API supplier certified by the international community in just over 15 years. Its investment in WHO-GMP compliance and an export-focused business model helped improve margins. The company supplies manufacturers across Africa and Southeast Asia. These margins also supported its ongoing investment in capacity building. Their path leads straight to the Ghana park’s API manufacturing opportunity.
Morepen Laboratories — Vertical Integration from Generics to Diagnostics
Morepen Laboratories started as a small generics manufacturer. It later expanded into API manufacturing and diagnostics through the Dr. Morepen brand of glucometers and blood pressure monitors. This multi-vertical approach aligns with the purpose of industrial park ecosystems. It helps companies capture value across the pharma supply chain rather than at a single stage. Early-mover tenants in Ghana’s industrial park ecosystem are expected to follow a similar strategy.
Discover business ideas that actually make money
How NPCS – Niir Project Consultancy Services Supports Your Market Entry
NPCS (Niir Project Consultancy Services) is India’s leading industrial consultancy and project report provider, with four decades of experience supporting entrepreneurs, MSMEs, and investors in pharmaceutical, chemical, food, and manufacturing sectors.
For businesses planning to enter Ghana’s pharmaceutical industrial park ecosystem, NPCS prepares bankable Detailed Project Reports (DPRs) covering capital cost estimates, equipment selection, plant layout, regulatory pathway, and financial projections. NPCS also conducts full Feasibility Studies with market sizing, competition analysis, site assessment, and breakeven modelling — the analytical foundation needed before committing capital.
Technology Consultancy services include GMP-compliant facility design guidance, process technology sourcing, equipment supplier identification, and quality system setup support. Market Research Reports provide pricing benchmarks, competitive intelligence, off-take assessment, and market entry strategy specific to West African pharmaceutical markets.
Whether you are an Indian MSME evaluating Ghana as a manufacturing base, a Ghanaian entrepreneur seeking to establish a domestic pharmaceutical business within the park, or an investor assessing exposure to Africa’s fastest-growing industrial sector, NPCS provides the technical and commercial foundation to launch with confidence.
Industry Snapshot: Ghana Pharmaceutical Industrial Park
| Parameter | Details |
| Industry | Pharmaceutical Manufacturing, Medical Devices, Herbal Medicine, R&D |
| Park Location | Shai-Osudoku District, Greater Accra Region, Ghana |
| Project Scale | ~2,000 acres; township for up to 20,000 workers within first 5 years |
| Market Driver | Ghana imports ~70% of pharma needs; rising NCD burden; post-COVID supply resilience |
| MSME Opportunity | Generics, APIs, Herbal Medicine, Pharma Packaging, Medical Devices, Cold Chain |
| Export Potential | ECOWAS (16 nations, 430M+ people), AfCFTA, EU-ACP, AGOA |
| Govt Support | Tax holidays (GFZA), duty exemptions (GIPC), 24-Hour Economy facilitation |
| Tenant Pipeline | India, China, USA companies in discussion; Ghanaian diaspora health professionals |
| Timeline | Project development completing end-2026; full design & master planning follows |
| Risk Level | Medium — anchor investor confirmed; land acquisition model community-equity based |
| Growth Outlook | Strong — structural NCD demand, import substitution policy, ECOWAS export access |
Conclusion: The Window Is Open — But Not Indefinitely
Ghana’s pharmaceutical industrial park announcement, as reported by Citi Newsroom, represents something rare in emerging market industrial policy. It offers a credible, infrastructure-backed opportunity with confirmed government commitment and a signed anchor investor. The project also has a live international tenant pipeline.
The fundamentals are equally strong. Ghana has 70 per cent import dependence and rising demand for NCD medicines. The park also offers ECOWAS export access and community-equity land acquisition. These factors align in a way that few African industrial projects have managed before…
For entrepreneurs and manufacturers, the calculus is clear. The market need is documented. The government support is structured and concrete. The regional export market is 430 million people strong. And the window for first-mover positioning — before plots are allocated, before supply chains lock in, before anchor tenants occupy the best facilities — is open right now.
Every month of delay in planning, feasibility assessment, and stakeholder engagement narrows that window. The companies building relationships with the 24-Hour Economy Secretariat, obtaining feasibility reports, and mapping their technology partnerships today are the ones who will define West African pharmaceutical manufacturing tomorrow.